4//SEC Filing
Ackermann Michael 4
Accession 0001819790-21-000039
CIK 0001819790other
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 4:48 PM ET
Size
7.1 KB
Accession
0001819790-21-000039
Insider Transaction Report
Form 4
Ackermann Michael
Director10% Owner
Transactions
- Sale
Common Stock
2021-10-12$25.56/sh−1,116$28,525→ 1,220,199 total - Sale
Common Stock
2021-10-12$26.45/sh−4,517$119,475→ 1,215,682 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.08 to $26.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.12 to $26.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001791249
Filing Metadata
- Form type
- 4
- Filed
- Oct 13, 8:00 PM ET
- Accepted
- Oct 14, 4:48 PM ET
- Size
- 7.1 KB